Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome

Investigators analyzed the diagnostic performance of plasma cerebrospinal fluid and neurofilament light biomarkers in patients with Down syndrome and Alzheimer disease.

Source link

Related posts

The “Dark Beast” Behind Combat Trauma—a Clinician’s View


A Concussion Crisis in Law Enforcement?


Grand Rounds – August 13, 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World